Total Payments
$361,308
2024 Payments
$66,559
Companies
40
Transactions
734
Medicare Patients
5,637
Medicare Billing
$761,317
Payment Breakdown by Category
Other$303,428 (84.0%)
Travel$32,174 (8.9%)
Food & Beverage$14,696 (4.1%)
Consulting$10,980 (3.0%)
Education$29.58 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $192,147 | 69 | 53.2% |
| Compensation for serving as faculty or as a speaker for a medical education program | $55,310 | 15 | 15.3% |
| Travel and Lodging | $32,174 | 145 | 8.9% |
| Honoraria | $29,771 | 15 | 8.2% |
| Compensation for serving as faculty or as a speaker for a non-accredited and noncertified continuing education program | $26,200 | 7 | 7.3% |
| Food and Beverage | $14,696 | 477 | 4.1% |
| Consulting Fee | $10,980 | 5 | 3.0% |
| Education | $29.58 | 1 | 0.0% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Gilead Sciences, Inc. | $149,794 | 230 | $0 (2024) |
| Intercept Pharmaceuticals, Inc. | $119,897 | 126 | $0 (2024) |
| ABBVIE INC. | $41,182 | 158 | $0 (2024) |
| Merck Sharp & Dohme LLC | $17,928 | 34 | $0 (2023) |
| Madrigal Pharmaceuticals | $15,341 | 10 | $0 (2024) |
| Valeant Pharmaceuticals North America LLC | $7,601 | 7 | $0 (2017) |
| Ipsen Biopharmaceuticals, Inc | $6,419 | 6 | $0 (2024) |
| Takeda Pharmaceuticals U.S.A., Inc. | $496.41 | 30 | $0 (2024) |
| Janssen Biotech, Inc. | $418.12 | 33 | $0 (2024) |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | $313.33 | 17 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $66,559 | 120 | Gilead Sciences, Inc. ($36,889) |
| 2023 | $48,008 | 78 | INTERCEPT PHARMACEUTICALS, INC. ($28,255) |
| 2022 | $30,216 | 68 | Gilead Sciences, Inc. ($14,124) |
| 2021 | $49,043 | 47 | Intercept Pharmaceuticals, Inc. ($29,835) |
| 2020 | $8,930 | 25 | Gilead Sciences, Inc. ($8,639) |
| 2019 | $46,788 | 140 | AbbVie, Inc. ($16,899) |
| 2018 | $40,028 | 115 | Gilead Sciences, Inc. ($24,103) |
| 2017 | $71,738 | 141 | Gilead Sciences Inc ($25,406) |
All Payment Transactions
734 individual payment records from CMS Open Payments — Page 1 of 30
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/18/2024 | Madrigal Pharmaceuticals | REZDIFFRA (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,115.00 | General |
| Category: LIVER DISEASE | ||||||
| 12/18/2024 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $21.24 | General |
| 12/16/2024 | Salix Pharmaceuticals, a division of Bausch Health US, LLC | XIFAXAN (Drug) | Food and Beverage | In-kind items and services | $18.78 | General |
| Category: Gastroenterology | ||||||
| 12/11/2024 | Ipsen Biopharmaceuticals, Inc | IQIRVO (Drug) | Honoraria | Cash or cash equivalent | $6,121.25 | General |
| Category: Rare Disease | ||||||
| 12/10/2024 | Madrigal Pharmaceuticals | REZDIFFRA (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,173.00 | General |
| Category: LIVER DISEASE | ||||||
| 12/10/2024 | Madrigal Pharmaceuticals | REZDIFFRA (Drug) | Food and Beverage | In-kind items and services | $150.00 | General |
| Category: LIVER DISEASE | ||||||
| 12/10/2024 | AIMMUNE THERAPEUTICS, INC. | VOWST (Biological) | Food and Beverage | In-kind items and services | $36.07 | General |
| Category: GI | ||||||
| 12/05/2024 | Takeda Pharmaceuticals U.S.A., Inc. | EOHILIA (Drug) | Food and Beverage | In-kind items and services | $15.97 | General |
| Category: INTERNAL MEDICINE | ||||||
| 11/26/2024 | Madrigal Pharmaceuticals | REZDIFFRA (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,173.00 | General |
| Category: LIVER DISEASE | ||||||
| 11/26/2024 | Madrigal Pharmaceuticals | REZDIFFRA (Drug) | Food and Beverage | In-kind items and services | $121.97 | General |
| Category: LIVER DISEASE | ||||||
| 11/23/2024 | Ipsen Biopharmaceuticals, Inc | IQIRVO (Drug) | Food and Beverage | In-kind items and services | $54.91 | General |
| Category: Rare Disease | ||||||
| 11/23/2024 | Ipsen Biopharmaceuticals, Inc | IQIRVO (Drug) | Food and Beverage | In-kind items and services | $45.38 | General |
| Category: Rare Disease | ||||||
| 11/23/2024 | Ipsen Biopharmaceuticals, Inc | IQIRVO (Drug) | Travel and Lodging | In-kind items and services | $41.30 | General |
| Category: Rare Disease | ||||||
| 11/20/2024 | Madrigal Pharmaceuticals | REZDIFFRA (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,173.00 | General |
| Category: LIVER DISEASE | ||||||
| 11/20/2024 | Madrigal Pharmaceuticals | REZDIFFRA (Drug) | Food and Beverage | In-kind items and services | $104.30 | General |
| Category: LIVER DISEASE | ||||||
| 11/20/2024 | Madrigal Pharmaceuticals | RESMETIROM (Drug) | Food and Beverage | In-kind items and services | $17.00 | General |
| Category: LIVER DISEASE | ||||||
| 11/20/2024 | ABBVIE INC. | SKYRIZI (Biological), RINVOQ, HUMIRA | Food and Beverage | In-kind items and services | $5.97 | General |
| Category: IMMUNOLOGY | ||||||
| 11/15/2024 | ABBVIE INC. | SKYRIZI (Biological), RINVOQ | Food and Beverage | In-kind items and services | $27.31 | General |
| Category: IMMUNOLOGY | ||||||
| 11/13/2024 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $19.26 | General |
| 11/06/2024 | IRONWOOD PHARMACEUTICALS, INC | Linzess (Drug) | Food and Beverage | Cash or cash equivalent | $24.33 | General |
| Category: GI | ||||||
| 10/30/2024 | Gilead Sciences, Inc. | Livdelzi (Drug) | Travel and Lodging | In-kind items and services | $41.42 | General |
| Category: INFLAM | ||||||
| 10/30/2024 | Janssen Biotech, Inc. | TREMFYA (Drug), SIMPONI, SIMPONI ARIA | Food and Beverage | In-kind items and services | $24.47 | General |
| Category: Immunology | ||||||
| 10/30/2024 | Gilead Sciences, Inc. | Livdelzi (Drug) | Travel and Lodging | In-kind items and services | $24.00 | General |
| Category: INFLAM | ||||||
| 10/30/2024 | Gilead Sciences, Inc. | Livdelzi (Drug) | Food and Beverage | In-kind items and services | $12.77 | General |
| Category: INFLAM | ||||||
| 10/30/2024 | Gilead Sciences, Inc. | Livdelzi (Drug) | Travel and Lodging | In-kind items and services | $10.00 | General |
| Category: INFLAM | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 19 | 1,335 | 1,546 | $820,690 | $215,512 |
| 2022 | 18 | 1,379 | 1,601 | $644,990 | $191,255 |
| 2021 | 20 | 1,360 | 1,574 | $592,660 | $171,901 |
| 2020 | 21 | 1,563 | 1,866 | $651,890 | $182,648 |
Total Patients
5,637
Total Services
6,587
Medicare Billing
$761,317
Procedure Codes
100
All Medicare Procedures & Services
100 procedure records from CMS Medicare Utilization — Page 1 of 4
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 317 | 470 | $109,805 | $42,287 | 38.5% |
| 45385 | Removal of polyps or growths of large bowel using an endoscope with mechanical snare | Office | 2023 | 69 | 69 | $84,890 | $25,823 | 30.4% |
| 45380 | Biopsy of large bowel using a flexible endoscope | Office | 2023 | 91 | 91 | $83,870 | $25,693 | 30.6% |
| 43239 | Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope | Office | 2023 | 76 | 77 | $61,660 | $19,188 | 31.1% |
| G0105 | Colorectal cancer screening; colonoscopy on individual at high risk | Office | 2023 | 57 | 57 | $48,270 | $18,360 | 38.0% |
| G0121 | Colorectal cancer screening; colonoscopy on individual not meeting criteria for high risk | Office | 2023 | 36 | 36 | $29,860 | $11,526 | 38.6% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 60 | 68 | $22,025 | $8,788 | 39.9% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 55 | 58 | $22,040 | $7,814 | 35.5% |
| 45385 | Removal of polyps or growths of large bowel using an endoscope with mechanical snare | Facility | 2023 | 38 | 38 | $45,980 | $7,592 | 16.5% |
| 45380 | Biopsy of large bowel using a flexible endoscope | Facility | 2023 | 45 | 45 | $40,970 | $5,352 | 13.1% |
| 99222 | Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | Facility | 2023 | 52 | 52 | $13,780 | $5,174 | 37.6% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 66 | 83 | $13,695 | $4,923 | 35.9% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 65 | 76 | $13,340 | $4,923 | 36.9% |
| 43239 | Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope | Facility | 2023 | 65 | 68 | $52,740 | $4,486 | 8.5% |
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 29 | 37 | $8,695 | $3,420 | 39.3% |
| G0105 | Colorectal cancer screening; colonoscopy on individual at high risk | Facility | 2023 | 19 | 19 | $15,390 | $3,363 | 21.9% |
| 43249 | Balloon dilation of esophagus, stomach, and/or upper small bowel using a flexible endoscope, less than 3.0 cm | Facility | 2023 | 29 | 33 | $64,200 | $3,301 | 5.1% |
| 43235 | Diagnostic exam of esophagus, stomach, and/or upper small bowel using a flexible endoscope | Facility | 2023 | 30 | 30 | $19,800 | $2,434 | 12.3% |
| 45378 | Diagnostic exam of large bowel using a flexible endoscope | Office | 2023 | 12 | 12 | $10,420 | $2,313 | 22.2% |
| 45378 | Diagnostic exam of large bowel using a flexible endoscope | Facility | 2023 | 18 | 18 | $14,580 | $2,207 | 15.1% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 16 | 16 | $5,440 | $1,944 | 35.7% |
| 99203 | New patient office or other outpatient visit, 30-44 minutes | Office | 2023 | 23 | 23 | $5,130 | $1,780 | 34.7% |
| 99231 | Subsequent hospital care with straightforward or low level of medical decision making, per day, if using time, at least 25 minutes | Facility | 2023 | 32 | 35 | $3,270 | $1,347 | 41.2% |
| 45381 | Injection beneath lining of large bowel using a flexible endoscope | Office | 2023 | 14 | 14 | $12,310 | $1,206 | 9.8% |
| 45381 | Injection beneath lining of large bowel using a flexible endoscope | Facility | 2023 | 21 | 21 | $18,530 | $267.82 | 1.4% |
About Dr. Michael Ryan, M.D
Dr. Michael Ryan, M.D is a Gastroenterology healthcare provider based in Norfolk, Virginia. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 12/15/2005. The National Provider Identifier (NPI) number assigned to this provider is 1962488668.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Michael Ryan, M.D has received a total of $361,308 in payments from pharmaceutical and medical device companies, with $66,559 received in 2024. These payments were reported across 734 transactions from 40 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($192,147).
As a Medicare-enrolled provider, Ryan has provided services to 5,637 Medicare beneficiaries, totaling 6,587 services with total Medicare billing of $761,317. Data is available for 4 years (2020–2023), covering 100 distinct procedure/service records.
Ad
Practice Information
- Specialty Gastroenterology
- Location Norfolk, VA
- Active Since 12/15/2005
- Last Updated 08/22/2007
- Taxonomy Code 207RG0100X
- Entity Type Individual
- NPI Number 1962488668
Products in Payments
- OCALIVA (Drug) $103,820
- Epclusa (Drug) $86,220
- Mavyret (Drug) $21,645
- Livdelzi (Drug) $19,620
- ZEPATIER (Drug) $17,743
- OCA (Drug) $16,077
- REZDIFFRA (Drug) $15,324
- MAVYRET (Drug) $12,236
- XIFAXAN (Drug) $7,772
- IQIRVO (Drug) $6,419
- Harvoni (Drug) $5,588
- Vosevi (Drug) $4,161
- Viekira (Drug) $2,199
- STELARA (Biological) $642.85
- Humira (Biological) $330.78
- ENTYVIO (Biological) $286.87
- RINVOQ (Biological) $205.20
- SKYRIZI (Biological) $195.62
- CONMED BILIARY (Device) $172.71
- DIFICID (Drug) $162.82
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Gastroenterology Doctors in Norfolk
Dr. David Johnson, M.d, M.D
Gastroenterology — Payments: $90,913
Gastroenterology $90,913
Alan Gamsey, M.d, M.D
Gastroenterology — Payments: $17,180
Gastroenterology $17,180
Satyanisth Agrawal, D.o, D.O
Gastroenterology — Payments: $16,097
Gastroenterology $16,097
Dr. Alex Williams, M.d, M.D
Gastroenterology — Payments: $9,534
Gastroenterology $9,534
Dr. Frank Wootton, M.d, M.D
Gastroenterology — Payments: $6,540
Gastroenterology $6,540
Dr. Kelvin Hornbuckle, M.d, M.D
Gastroenterology — Payments: $5,730
Gastroenterology $5,730